Endocrine Abstracts

Aim: To study the effectiveness of metformin in treatment of polycystic ovaries syndrome (PCOS) in women of birthing age.

Materials and methods: We followed 31 women with PCOS. Mean age of patients was 29.8 years old. All patients were evaluated for hormones levels (LH, FSH, TSH, estradiol, progesterone, testosterone, prolactin, coritsole, free thyroxine, dehydroepiahndrostendione etc.), glucose tolerance test, lipids profile, uterus and ovaries ultrasonography, pituitary MRI etc.

All these evaluations were repeated in 6 months after metformin therapy. Medication was given 500 mg³ times a day during meals for 6 months.

Results: Before treatment patients had significant changes both in hormonal and imaging evaluations. Hyperandrogenemia was revealed in 83.8%, hyperprolactinemia in 77.4%, elevated LH in (48.3%), hypoestrogenemia in 93.5% of patients. Of all patients, 23 females (74.1%) had impaired glucose tolerance test, whereas 16 women 51.6% had dyslipidemia. 22 patients (70.9%) had increased body mass and 13 women (41.9%) had arterial hypertension indicating that these patients with PCOS had metabolic syndrome.

In 6 months’ time after therapy with metformin we observed reliable bilateral improvement of ovaries structure, including cysts regression, size normalization in all of patients (100%), while laboratory and hormonal measurements improved in 29 patients (93.5%), whereas body mass decreased in 20 women (90%) of 22.

Conclusion: (1) Metformin therapy significantly improves clinical and biochemical values in women with PCOS which confirmed by ultrasonography (2) it should be recommended to administer metformin therapy to women with PCOS in short breaks (3 months).

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.